Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce a public whistleblower policy with a potential cash reward of up to USD $7 million to any individual or entity who can provide definitive and verifiable proof that they were asked, instructed, hired, or otherwise induced to manipulate the Company’s stock. The following individuals or entities are not eligible to receive rewards: 1) current directors, officers, or employees of the Company; 2) members of law enforcement, regulatory agencies, or government officials acting in an official capacity; 3) individuals who obtained information unlawfully or in violation of legal or professional duties; and 4) individuals who knowingly submit false, misleading, or fabricated information. The Company will not use the information until the information provider gives consent to the Company to use the information. Those with information can submit directly to reward@quantumbiopharma.com or call 1-833-571-1811.

When formulating this whistleblower reward and policy, Quantum BioPharma received legal opinions and comprehensive advice from multiple law firms/legal counsel, as well as the approval of its audit committee and its board of directors.

The cash reward of up to USD $7 million will be paid if that information tangibly and significantly contributes evidence which leads to a final, non‑appealable judgment in favour of the Company, or a binding settlement. This information includes, but is not limited to, evidence of tactics used such as: 1) illegal “spoofing” trades or, at another’s behest; 2) the deliberate spreading of false or misleading information about the Company across the internet; 3) selling shares that are not timely delivered; and 4) lending shares you do not have.

The whistleblower reward will only be paid out from the net proceeds of the Company’s ongoing lawsuit, once resolved. This reward can be shared between multiple parties providing different information.

The determination of any reward amount is at the Company’s discretion and based on the significance and impact of the information. Any information provided will be kept confidential, unless required by law. Information will only be used once written consent has been obtained.

The lawsuit, and this whistleblower reward, underscore the Company’s commitment to holding alleged perpetrators accountable, and helping restore market integrity.

This reward program does not limit, replace, or interfere with the United States Securities and Exchange Commission (“SEC”) Whistleblower Program or whistleblower programs operated by Canadian regulatory authorities. Individuals remain free to report…